American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 42-49 , January 2010

Effect of Lovastatin on Primary Prevention of Cardiovascular Events in Mild CKD and Kidney Function Loss: A Post Hoc Analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study

  • Jessica Kendrick, MD

      Affiliations

    • Division of Renal Diseases and Hypertension, University of Colorado Denver Health Sciences Center, Aurora, CO
    • ,
  • Michael G. Shlipak, MD, MPH

      Affiliations

    • General Internal Medicine Section, Veterans Affairs Medical Center, University of California, San Francisco, CA
    • ,
  • Giovanni Targher, MD

      Affiliations

    • Section of Endocrinology, Department of Biomedical and Surgical Sciences, University of Verona Hospital, Verona, Italy
    • ,
  • Thomas Cook, MS

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • ,
  • Joann Lindenfeld, MD

      Affiliations

    • Division of Cardiology, University of Colorado Denver Health Sciences Center, Aurora, CO
    • ,
  • Michel Chonchol, MD

      Affiliations

    • Division of Renal Diseases and Hypertension, University of Colorado Denver Health Sciences Center, Aurora, CO
    • Corresponding Author InformationAddress correspondence to Michel Chonchol, MD, Division of Renal Diseases and Hypertension, University of Colorado Denver Health Sciences Center, 4545 E. 9th Ave, Denver, CO, 80220

Received 29 April 2009 ,Accepted 14 September 2009.

References 

  1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  2. Menon V, Sarnak MJ. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Am J Kidney Dis. 2005;45:223–232
  3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  4. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663
  5. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl. 1991;31:S29–S34
  6. Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int. 2008;74:571–576
  7. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  8. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645–651
  9. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–1563
  10. Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98–104
  11. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605–1613
  12. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–178
  13. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA. 1998;279:1615–1622
  14. Downs JR, Beere PA, Whitney E, et al. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 1997;80:287–293
  15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  16. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121–1129
  17. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol. 2005;16:529–538
  18. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315
  19. Clearfield M, Whitney EJ, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. J Cardiovasc Risk. 2000;7:125–133
  20. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  21. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  22. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int. 1990;37:880–891
  23. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–2091

 Originally published online as doi:10.1053/j.ajkd.2009.09.020 on November 23, 2009.

 Because the Editor-in-Chief recused himself from consideration of this manuscript, the Deputy Editor (Daniel E. Weiner, MD, MS) served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(09)01274-8

doi: 10.1053/j.ajkd.2009.09.020

American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 42-49 , January 2010

Article Tools

* Image Usage & Resolution